Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RenovoRx, Inc.RNXT · Entity 6797 | VP, Controller and PAO | July 01, 2025 | July 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RenovoRx, Inc.
Report date July 01, 2025 · Filed July 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.27 | Direct | 41,600 |
Reported balance
After 2025-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-01 · Grant · Acquired 41,600 · Balance 41,600 F1: Represents an award of 41,600 incentive stock options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 41,600 incentive stock options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2025 Filed Jul 3, 2025 16:45 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 41,600 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001641172-25-017830 · ownership.xml · derivative · entry 1 Kocak Ron · CIK 0002011160 · VP, Controller and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,600 Underlying: Common Stock · 41,600 shares Expires not disclosed F1 · derivative.exercise_date: Represents an award of 41,600 incentive stock options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. F1 · derivative.expiration_date: Represents an award of 41,600 incentive stock options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 17:18 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 166,400 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001641172-25-005109 · ownership.xml · derivative · entry 1 Kocak Ron · CIK 0002011160 · VP, Controller and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,400 Underlying: Common Stock · 166,400 shares Expires not disclosed F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted an incentive stock option to purchase up to 166,400 shares of the Issuer's common stock, with such option vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on April 14, 2035. F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted an incentive stock option to purchase up to 166,400 shares of the Issuer's common stock, with such option vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on April 14, 2035. Read SEC document |
| April 10, 2025 Filed Apr 10, 2025 19:02 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 6,500 | $0.79 | $5,135.00 |
DisclosureSEC source: 0001641172-25-003675 · ownership.xml · nonDerivative · entry 3 Kocak Ron · CIK 0002011160 · VP Controller and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,595 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 19:02 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 6,000 | $0.80 | $4,800.00 |
DisclosureSEC source: 0001641172-25-003675 · ownership.xml · nonDerivative · entry 2 Kocak Ron · CIK 0002011160 · VP Controller and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,095 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 19:02 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 95 | $0.80 | $76.00 |
DisclosureSEC source: 0001641172-25-003675 · ownership.xml · nonDerivative · entry 1 Kocak Ron · CIK 0002011160 · VP Controller and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 19:46 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantOptions · Derivative | 15,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001493152-24-005939 · ownership.xml · derivative · entry 1 Kocak Ron · CIK 0002011160 · VP, Controller and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · price: Represents 10-year incentive stock options to purchase 15,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning vesting on the date. F1 · derivative.exercise_date: Represents 10-year incentive stock options to purchase 15,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning vesting on the date. F1 · derivative.expiration_date: Represents 10-year incentive stock options to purchase 15,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning vesting on the date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.